Statera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that play a key role in the innate immune system.
Company profile
Ticker
STAB
Exchange
Website
CEO
Christopher Zosh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CLEVELAND BIOLABS INC, Cytocom, Inc.
SEC CIK
Corporate docs
Subsidiaries
ImQuest Life Sciences, Inc. • ImQuest BioSciences, Inc. • ImQuest Pharmaceuticals, Inc. • Lubrinovation Inc. • Panacela Labs, Inc. • Panacela Labs LLC ...
IRS number
200077155
STAB stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
3 Mar 23
DEFR14A
Revised proxy
28 Feb 23
DEF 14A
Definitive proxy
27 Feb 23
PRE 14A
Preliminary proxy
15 Feb 23
8-K
Material Modifications to Rights of Security Holders
1 Feb 23
8-A12G
Registration of securities
1 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Jan 23
DEF 14A
Definitive proxy
28 Nov 22
PRE 14A
Preliminary proxy
18 Nov 22
8-K
Entry into a Material Definitive Agreement
15 Nov 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 506.10 k | 506.10 k | 506.10 k | 506.10 k | 506.10 k | 506.10 k |
Cash burn (monthly) | 15.89 k | 1.14 mm | 515.48 k | 7.35 mm | 267.17 k | 1.01 mm |
Cash used (since last report) | 299.34 k | 21.53 mm | 9.71 mm | 138.49 mm | 5.03 mm | 18.99 mm |
Cash remaining | 206.76 k | -21.02 mm | -9.21 mm | -137.99 mm | -4.53 mm | -18.48 mm |
Runway (months of cash) | 13.0 | -18.4 | -17.9 | -18.8 | -16.9 | -18.3 |
Institutional ownership, Q3 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 1.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tucker Asset Management | 1.00 k | $0.00 |
Proequities | 0.00 | $0.00 |